SOUL study showed Rybelsus® (semaglutide) tablets 14 mg reduced the risk of major adverse cardiovascular events (MACE) by 14% (ARR 2% absolute risk reduction at 3 years) vs placebo in adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney...
Read More Details
Finally We wish PressBee provided you with enough information of ( Oral semaglutide 14 mg demonstrated superior reduction in risk of cardiovascular events in late-breaking SOUL trial presented at the American College of Cardiology )
Also on site :
- On the record: Hubbard
- ForexLive Asia-Pacific FX news wrap: Oil spike on talk of Israel preparing attack on Iran
- CNN Confession: Jake Tapper Admits Conservative Media Was Right About Biden’s Cognitive Decline